NRX Pharmaceuticals Inc

NAS:NRXP (USA)   Ordinary Shares
$ 0.29 -0.1347 (-31.5%) 11:35 AM EST
At Loss
Market Cap:
$ 36.42M
Enterprise V:
$ 38.64M
Volume:
3.29M
Avg Vol (2M):
667.07K
Also Trade In:
Volume:
3.29M
At Loss
Avg Vol (2M):
667.07K

Business Description

NRX Pharmaceuticals Inc
NAICS : 541714 SIC : 2834
ISIN : US6294441000

Share Class Description:

NRXP: Ordinary Shares
Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.
Name Current Vs Industry Vs History
Cash-To-Debt 0.88
Equity-to-Asset -0.47
Debt-to-Equity -1.62
Debt-to-EBITDA -0.28
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 28.1
9-Day RSI 42.34
14-Day RSI 47.39
6-1 Month Momentum % 19.47
12-1 Month Momentum % -61.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.68
Quick Ratio 0.68
Cash Ratio 0.46

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % -50.87
Name Current Vs Industry Vs History
ROE % -1211.5
ROA % -171.16
ROIC % -385.18
ROC (Joel Greenblatt) % -15593.94
ROCE % -1017.34

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -1.04
EV-to-Forward-EBIT -1.35
EV-to-EBITDA -1.04
EV-to-Forward-Revenue 5.41
EV-to-FCF -1.44
Earnings Yield (Greenblatt) % -96.15
FCF Yield % -73.55

Financials (Next Earnings Date:2024-03-06)

NRXP's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NRXP

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

NRX Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.5
Beta 0
Volatility % 78.64
14-Day RSI 47.39
14-Day ATR ($) 0.042165
20-Day SMA ($) 0.434755
12-1 Month Momentum % -61.78
52-Week Range ($) 0.221 - 1.2
Shares Outstanding (Mil) 85.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NRX Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

NRX Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

NRX Pharmaceuticals Inc Frequently Asked Questions

What is NRX Pharmaceuticals Inc(NRXP)'s stock price today?
The current price of NRXP is $0.29. The 52 week high of NRXP is $1.20 and 52 week low is $0.22.
When is next earnings date of NRX Pharmaceuticals Inc(NRXP)?
The next earnings date of NRX Pharmaceuticals Inc(NRXP) is 2024-03-06.
Does NRX Pharmaceuticals Inc(NRXP) pay dividends? If so, how much?
NRX Pharmaceuticals Inc(NRXP) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1